Guardant Health reported a Q2 revenue jump driven by growth in oncology testing, including an expansion of colorectal screening volume. The company also highlighted the FDA’s June approval of Guardant360 Liquid CDx as a companion diagnostic for Boehringer Ingelheim’s Hernexeos in HER2-mutant advanced non-small cell lung cancer, alongside updates to U.S. colorectal screening guidelines and new payer coverage for its Shield test.